At ResMed, we strive to develop our patient expertise and experience. With our programme to research clinical areas related to sleep-disordered breathing, we aim to further develop our in-depth knowledge on sleep and respiratory disorders. That’s why we support and actively engage in research initiatives on COPD.
ResMed is supporting multiple global trials investigating morbidity and mortality benefits, as well as biomarkers, quality of life and other outcomes in COPD patients treated with non-invasive ventilation (NIV).
Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation (HOmeVent)
The prevalence of chronic respiratory disease, including COPD, is increasing in industrialised countries. Over the next decade, deaths from COPD are projected to increase by more than 30% and COPD will become the third leading cause of death worldwide by 2030. There is robust scientific evidence that non-invasive ventilation (NIV) therapy is an effective option for most COPD patients hospitalised with acute hypercapnic respiratory failure secondary to an acute disease exacerbation. More recently, NIV has been shown to significantly improve survival and quality of life in COPD patients with chronic stable hypercapnic disease. These data represent an important advance in the field, and indicate that usage of NIV in patients with chronic stable hypercapnic COPD should increase. Such an increase would be expected to improve patient outcomes and have a beneficial impact on the significant healthcare burden incurred by these patients. However, the proportion of stable COPD patients with chronic hypercapnia is unknown. In addition, using NIV at home to treat COPD patients with hypercapnic (type 2) respiratory failure has not often been considered previously and there is a paucity of data regarding NIV usage patterns over time in this setting. This prospective COPD registry will enable assessment of the prevalence of hypercapnia in stable COPD patients, describe home NIV usage patterns, and evaluate the effects of home NIV on outcome.
eCOPD is one of our studies which aims to evaluate the long-term efficacy and benefits of telemonitored NIV treatment on COPD patients.
We expect to test 80 patients with a one-year follow-up.
For clinical literature on COPD, consult our dedicated ResMed page.